Decisive point for gensight in the short termSolid'action which is about to exceed probably € 10 in the short term if we go above € 9.35 at 11:45 am.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.3535 EUR
−26.22 M EUR
1.27 M EUR
89.14 M
About GENSIGHT BIOLOGICS
Sector
CEO
Laurence Rodriguez
Headquarters
Paris
Website
Founded
2012
ISIN
FR0013183985
FIGI
BBG00D8N3240
GenSight Biologics SA is a clinical-stage gene therapy company, which engages in research and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye. It also focuses on central nervous system diseases. The company was founded by Bernard Jacques Alex Gilly, Botond Roska, Jean Bennett, Connie Cepko, Luk H. Vandenberghe, Serge Picaud and Jose-Alain Sahel in 2012 and is headquartered in Paris, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SIGHT is 0.3100 EUR — it has decreased by −2.04% in the past 24 hours. Watch GENSIGHT BIOLOGICS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange GENSIGHT BIOLOGICS stocks are traded under the ticker SIGHT.
SIGHT stock has fallen by −0.79% compared to the previous week, the month change is a −10.71% fall, over the last year GENSIGHT BIOLOGICS has showed a −33.76% decrease.
We've gathered analysts' opinions on GENSIGHT BIOLOGICS future price: according to them, SIGHT price has a max estimate of 0.36 EUR and a min estimate of 0.36 EUR. Watch SIGHT chart and read a more detailed GENSIGHT BIOLOGICS stock forecast: see what analysts think of GENSIGHT BIOLOGICS and suggest that you do with its stocks.
SIGHT reached its all-time high on Sep 2, 2016 with the price of 10.8200 EUR, and its all-time low was 0.2800 EUR and was reached on Oct 23, 2024. View more price dynamics on SIGHT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SIGHT stock is 5.25% volatile and has beta coefficient of 1.11. Track GENSIGHT BIOLOGICS stock price on the chart and check out the list of the most volatile stocks — is GENSIGHT BIOLOGICS there?
Today GENSIGHT BIOLOGICS has the market capitalization of 36.74 M, it has decreased by −8.09% over the last week.
Yes, you can track GENSIGHT BIOLOGICS financials in yearly and quarterly reports right on TradingView.
GENSIGHT BIOLOGICS is going to release the next earnings report on Mar 21, 2025. Keep track of upcoming events with our Earnings Calendar.
SIGHT net income for the last half-year is −5.85 M EUR, while the previous report showed −14.24 M EUR of net income which accounts for 58.93% change. Track more GENSIGHT BIOLOGICS financial stats to get the full picture.
No, SIGHT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 16.00 employees. See our rating of the largest employees — is GENSIGHT BIOLOGICS on this list?
Like other stocks, SIGHT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENSIGHT BIOLOGICS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENSIGHT BIOLOGICS technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENSIGHT BIOLOGICS stock shows the sell signal. See more of GENSIGHT BIOLOGICS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.